Welcome to Circassia
Circassia is a specialty biopharmaceutical company focused on developing world-class immunotherapies. These include a new class of synthetic T-cell allergy treatments designed to treat a broad range of allergies, and therapies to combat autoimmune conditions such as rheumatoid arthritis and psoriasis. The Company has made rapid progress since its establishment in 2007, and several of its products are currently in mid- to late-stage development, having successfully completed a number of phase II clinical studies.
Circassia’s history
Circassia was originally founded to develop and commercialise a range of T-cell allergy treatments based on the Company’s proprietary ToleroMune® technology, which has the potential to transform current treatment. With its portfolio of T-cell allergy treatments progressing rapidly through clinical development, Circassia has broadened its pipeline into other areas of immunotherapy. These include treatments for autoimmune diseases, with the Company initially focusing on rheumatoid arthritis and psoriasis.
Circassia’s team
Circassia is managed by a strong team of life science entrepreneurs and scientists who bring a wealth of experience from major pharmaceutical and biotechnology companies as well as the specialty pharmaceutical sector. Circassia is well funded having raised £72m through a second tranche of fund raising in April 2012 and is supported by a syndicate of leading institutional and venture capital investors.
Did you know?
Over 12% of the population are allergic to cats